Similarly, anti-PD-1 and anti-PD-L1 ICIs serve to block binding at the PD-1/PD-L1 or PD-1/PD-L2 checkpoints and prevent the interaction between T cells and other immune cells (e.g., B cells, myeloid cells) expressing PD-1 and tumor cells, APCs, and other immune cells expressing PD-1 ligands [45]. This evidence concerns the gene CD274 and neoplasm.